Biotechnology News and Research

RSS

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

DuPont and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.

23 Sep 2010

DCGI approves ADXS11-001 human testing for cervix cancer

As part of approving the human testing of ADXS11-001 the lead agent for the treatment of cervix cancer of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use.

23 Sep 2010

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Evotec AG today announced that it has entered into a collaboration with Almirall S.A. to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

23 Sep 2010

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.

23 Sep 2010

Study may help develop preventative treatments for womb infections

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have established in mice the mechanism that detects and responds to the presence of bacteria in the womb a discovery that opens up the possibility of new preventative treatments for diseases like pelvic inflammatory disease and Chlamydia.

23 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.

23 Sep 2010

BioMed to acquire two adjacent life science campuses in South San Francisco

BioMed Realty Trust, Inc. today announced that it has entered into a definitive agreement to acquire two adjacent life science campuses in South San Francisco: the Science Center at Oyster Point and the Gateway Business Park.

23 Sep 2010

pSivida reports $8.8 million consolidated net income for 2010 fiscal year

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back of the eye diseases, including the product candidate Iluvien for the treatment of Diabetic Macular Edema, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.

23 Sep 2010

Biomatrica launches DNAgard Blood and DNAstable Blood sample stabilization products

Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.

22 Sep 2010

Shrink Nanotechnologies leases laboratory space inside TechPortal

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.

22 Sep 2010

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

NIH awards UCSF $15.4 million to set up new National Center for Systems Biology

Cell biologists at UCSF have received $15.4 million from the National Institutes of Health to set up one of two new National Centers for Systems Biology, to study how cells respond to their environment - an emerging field of research that could revolutionize medicine by creating "smart cells" to deliver medications and other therapeutics more effectively.

22 Sep 2010

Five Prime Therapeutics receives patent for lead oncology product

Five Prime Therapeutics, Inc. today announced it has been issued two patents, U.S. Patent No. 7,678,890 and European Patent No.1910542B1, with claims covering various engineered Fibroblast Growth Factor Receptor ("FGFR") fusion proteins, including composition of matter claims for its lead oncology product, FP-1039.

21 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

ImmunoGen commences clinical testing with SAR566658 anticancer compound

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.

21 Sep 2010

KIKA provides Veracity advanced EDC platform for Clinical Asset Management

KIKA Clinical Solutions will welcome customers and partners who are driving the adoption of EDC for clinical trials at its second annual U.S. User Group Meeting in Boston, Mass., October 19 and 20. KIKA provides the Veracity advanced EDC platform for Clinical Asset Management to the pharmaceutical, biotechnology and medical device industries.

21 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010